Rilonacept
- TRADE NAME: Arcalyst (Regeneron)
- INDICATIONS: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS)
- CLASS: Fusion protein, Interleukin-1 inhibitor
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
anti-TNF agents, Lenalidomide, live vaccines, Natalizumab
PREGNANCY CATEGORY: C
Cryopyrin-associated periodic syndromes (CAPS) are characterized by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. Intermittent, disruptive exacerbations or flares can be triggered at any time by exposure to cooling temperatures, stress, exercise, or other unknown stimuli.
Please login to see the rest of this drug profile
CENTRAL NERVOUS SYSTEM.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric